What is the recommended intravenous immunoglobulin (IVIG) regimen for Guillain‑Barré syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IVIG Regimen for Guillain-Barré Syndrome

Administer IVIG at 0.4 g/kg body weight daily for 5 consecutive days (total dose 2 g/kg). This is the standard, evidence-based regimen for GBS treatment 1.

Dosing Details

The recommended regimen is straightforward:

  • Dose: 0.4 g/kg/day
  • Duration: 5 consecutive days
  • Total cumulative dose: 2 g/kg
  • Infusion rate: Start at 0.01 mL/kg/min (0.5 mg/kg/min), gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated 1, 2

This dosing is equally effective as plasma exchange (200-250 mL plasma/kg over 5 sessions) but is generally preferred because it's easier to administer and more widely available 1.

Critical Considerations by Patient Population

Pediatric Patients

Use the same adult regimen (0.4 g/kg/day for 5 days) 1. Do not use the 2-day regimen (2 g/kg over 2 days) despite some centers using it—one study showed treatment-related fluctuations occurred in 22% (5/23) of children with the 2-day regimen versus 0% with the 5-day regimen 1.

Pregnant Women

IVIG is not contraindicated during pregnancy and is actually preferred over plasma exchange, which requires additional monitoring 1.

Patients at Risk for Thrombosis or Renal Dysfunction

Administer at the minimum infusion rate practicable and ensure adequate hydration before treatment 2. Monitor closely for signs of thrombosis, especially in patients with advanced age, immobilization, hypercoagulable states, or cardiovascular risk factors 2.

What NOT to Do

Avoid these common pitfalls:

  • Do not give combination therapy (plasma exchange followed by IVIG)—it provides no additional benefit over either treatment alone 1
  • Do not add corticosteroids—eight randomized trials showed no benefit, and oral corticosteroids actually worsened outcomes 1
  • Do not routinely give a second course of IVIG unless there is treatment-related fluctuation (TRF) within 8 weeks 3. Evidence for repeat dosing in non-responders is insufficient 4

Special Variants

Miller Fisher Syndrome (MFS)

Treatment is generally not recommended for pure MFS, as most patients recover completely within 6 months without treatment. However, monitor closely as some develop limb weakness, bulbar palsy, or respiratory failure requiring treatment 1.

Other GBS Variants

For Bickerstaff brainstem encephalitis (BBE) and other clinical variants, IVIG or plasma exchange is justified, though evidence is limited 1.

When Treatment May Be Insufficient

Approximately 25% of patients require mechanical ventilation and 20% cannot walk unaided at 6 months despite standard treatment 1. Patients with only minor increases in serum IgG levels after standard IVIG recover significantly slower 5. However, the evidence does not support routine repeat IVIG in non-responders—a 2025 systematic review found no beneficial effect of further IVIG in unresponsive GBS 4.

For patients with treatment-related fluctuations (secondary deterioration within 8 weeks), repeated IVIG is appropriate 3. About 5% of patients initially diagnosed with GBS actually have acute-onset CIDP (A-CIDP), which requires different long-term management 3.

Monitoring During Infusion

Monitor vital signs throughout the infusion. If adverse reactions occur, slow or stop the infusion. Once symptoms subside, resume at a lower rate that the patient tolerates 2. Watch particularly for signs of hypersensitivity, thrombosis, renal dysfunction, and hemolysis 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.